Correlation of Baseline BCL-2 mRNA Expression and Clinical Response to Neoadjuvant Chemotherapy in Breast Cancer

Authors

  • Prihantono Prihantono Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Mochammad Hatta Molecular Biology and Immunology Laboratory, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Daniel Sampepajung Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Andi Asadul Islam Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Warsinggih Rahardjo Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • William Hamdani Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Burhanuddin Bahar Department of Epidemiology, Faculty of Health, HasanuddinUniversity, Makassar, Indonesia
  • Eddy Herman Tanggo Department of Surgery, Faculty of Medicine, Airlangga University, Surabaya, Indonesia
  • Upik Anderiani Miskad Department of Pathology Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Keywords:

Breast Cancer, Chemotherapy, Clinical Response, mRNA, BCL-2, qRT-PCR.

Abstract

Background: Impairment of apoptosis is a hallmark of cancer. Tumor resistance to apoptosis usually caused by deregulation of the expression of BCL-2 family protein or mutation of the tumor suppressor gene p53. Over expression of Bcl-2 is commonly found in various types of cancer including breast cancer. Studies mentioned that analysis of Bcl-2 might predict response to selected endocrine and chemotherapies. Purpose: Evaluation of correlation of BCL-2 mRNA expression and clinical response to neoadjuvant chemotherapy in breast cancer patients. Method: longitudinal study, 30 subjects of breast cancer tissue samples prechemotherapy using cyclophosphamide-adriamycin-5FU regiment.

Detection of mRNA expression of BCL-2 using qRT-PCR techniques.

References

. Yip K, Reed J. Bcl-2 family proteins and cancer. Oncogene. 2008;27(50):6398-406.

. Kumar R, Vadlamudi R, Adam L. Apoptosis in mammary gland and cancer. Endocrine-Related Cancer. 2000;7(4):257-69.

. Martinez-Arribas F, Alvarez T, Del Val G, Martin-Garabato E, N

. Adams J, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324-37.

. Tabuchi Y, Matsuoka J, Gunduz M, Imada T, Ono R, Ito M, et al. Resistance to paclitaxel therapy is related with Bc1-2 expression through an estrogen receptor mediated pathway in breast cancer. International journal of oncology. 2009;34(2):313.

. Savry A, Carre M, Berges R, Rovini A, Pobel I, Chacon C, et al. Bcl-2

. Kim T, Han W, Kim MK, Lee JW, Kim J, Ahn SK, et al. Predictive significance of p53, Ki-67, and Bcl-2 expression for pathologic complete response after neoadjuvant chemotherapy for triple-negative breast cancer. Journal of breast cancer. 2015;18(1):16-21.

. Dawson S-J, Makretsov N, Blows F, Driver K, Provenzano E, Le Quesne J, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. British journal of cancer. 2010;103(5):668-75.

. Abdel-Fatah T, Perry C, Dickinson P, Ball G, Moseley P, Madhusudan S, et al. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Annals of oncology. 2013;24(11):2801-7.

. Boom R, Sol C, Salimans M, Jansen C, Wertheim-van Dillen P, Van der Noordaa J. Rapid and simple method for purification of nucleic acids. Journal of clinical microbiology. 1990;28(3):495-503.

. Akl H, Vervloessem T, Kiviluoto S, Bittremieux M, Parys JB, De Smedt H, et al. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2014;1843(10):2240-52.

. Bonnefoy-Berard N, Aouacheria A, Verschelde C, Quemeneur L, Mar

. Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, et al. Sensitization of BCL-2

. Brahmbhatt H, Oppermann S, Osterlund EJ, Leber B, Andrews DW. Molecular Pathways: Leveraging the BCL-2 Interactome to Kill Cancer Cells

. Ohmori T, Podack E, Nishio K, Takahashi M, Miyahara Y, Takeda Y, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochemical and biophysical research communications. 1993;192(1):30-6.

. Castiglione F, Sarotto I, Fontana V, Destefanis M, Venturino A, Ferro S, et al. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients. Anticancer research. 1998;19(5C):4555-63.

. Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, et al. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER?positive breast cancer. The Journal of pathology. 2012;226(1):97-107.

. Van Slooten H, Clahsen P, Van Dierendonck J, Duval C, Pallud C, Mandard A, et al. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. British journal of cancer. 1996;74(1):78.

Downloads

Published

2017-01-11

How to Cite

Prihantono, P., Hatta, M., Sampepajung, D., Islam, A. A., Rahardjo, W., Hamdani, W., Bahar, B., Tanggo, E. H., & Miskad, U. A. (2017). Correlation of Baseline BCL-2 mRNA Expression and Clinical Response to Neoadjuvant Chemotherapy in Breast Cancer. International Journal of Sciences: Basic and Applied Research (IJSBAR), 31(1), 157–164. Retrieved from https://www.gssrr.org/index.php/JournalOfBasicAndApplied/article/view/6787

Issue

Vol. 31 No. 1 (2017)

Section

Articles

License

Authors who submit papers with this journal agree to the following terms.